阿帕替尼治疗晚期化疗耐药胃癌的临床效果分析
|
摘要
目的分析晚期化疗耐药性胃癌应用阿帕替尼治疗的临床疗效。方法选择该院2016年3月—2018年3月收治的32例晚期化疗耐药性胃癌患者,根据治疗方法不同分为两组,观察组和对照组,各为16例,对照组采取常规化疗治疗,观察组在对照组的基础上采取阿帕替尼治疗,对两组治疗效果及不良反应情况进行对比分析。结果观察组经治疗后中位生存期为(12.15±2.96)个月显著长于对照组(8.51±2.05)个月,比较差异有统计学意义(t=5.866,P<0.05),观察组治疗后总有效率为81.25%(13/16)显著高于对照组43.75%(7/16),比较差异有统计学意义(χ~2=4.793,P<0.05);观察组经治疗后不良反应发生率12.50%(2/16)显著低于对照组31.25%(5/16),比较差异有统计学意义(χ~2=4.291,P<0.05)。结论阿帕替尼联合常规治疗可有效控制晚期化疗耐药性胃癌患者病情,抑制肿瘤细胞生长和再生,防止癌细胞进一步扩散,阿帕替尼安全性高,不易引起用药后不良反应,延长患者生存时间显著,具有较高的应用价值,可作为晚期化疗耐药性胃癌的首选治疗方案。
Objective To analyze the clinical effect of apatinib in treatment of advanced chemotherapy resistant gastric cancer. Methods 32 cases of patients with advanced chemotherapy resistant gastric cancer admitted and treated in our hospital from March 2016 to March 2018 were selected and divided into two groups with 16 cases in each, the control group were treated with routine chemotherapy, while the observation group were treated with apatinib on the basis of the control group, and the treatment effect and adverse reactions were compared between the two groups. Results The median survival time after treatment in the observation group was obviously longer than that in the control group[(12.15±2.96) months vs(8.51±2.05) months], and the difference was statistically significant(t=5.866, P<0.05), and the total effective rate after treatment in the observation group was obviously higher than that in the control group, [81.25%(13/16) vs 43.75%(7/16)], and the difference was obvious(χ~2=4.793, P<0.05), after treatment, the incidence rate of adverse reactions was obviously lower than that in the control group [12.50%(2/16) vs 31.25%(5/16)], and the difference was statistically significant(χ~2=4.291, P< 0.05). Conclusion The apatinib combined with routine therapy can effectively control the diseases of patients with advanced chemotherapy resistant gastric cancer, inhibite tumor cell growth and regeneration and prevent the further proliferation of cancer cell, with high safety of apatinib, without causing the adverse reactions after medication, and it can prolong the survival time of patients, with higher application value, and it can be used as the first treatment plan of advanced chemotherapy resistant gastric cancer.
Objective To analyze the clinical effect of apatinib in treatment of advanced chemotherapy resistant gastric cancer. Methods 32 cases of patients with advanced chemotherapy resistant gastric cancer admitted and treated in our hospital from March 2016 to March 2018 were selected and divided into two groups with 16 cases in each, the control group were treated with routine chemotherapy, while the observation group were treated with apatinib on the basis of the control group, and the treatment effect and adverse reactions were compared between the two groups. Results The median survival time after treatment in the observation group was obviously longer than that in the control group[(12.15±2.96) months vs(8.51±2.05) months], and the difference was statistically significant(t=5.866, P<0.05), and the total effective rate after treatment in the observation group was obviously higher than that in the control group, [81.25%(13/16) vs 43.75%(7/16)], and the difference was obvious(χ~2=4.793, P<0.05), after treatment, the incidence rate of adverse reactions was obviously lower than that in the control group [12.50%(2/16) vs 31.25%(5/16)], and the difference was statistically significant(χ~2=4.291, P< 0.05). Conclusion The apatinib combined with routine therapy can effectively control the diseases of patients with advanced chemotherapy resistant gastric cancer, inhibite tumor cell growth and regeneration and prevent the further proliferation of cancer cell, with high safety of apatinib, without causing the adverse reactions after medication, and it can prolong the survival time of patients, with higher application value, and it can be used as the first treatment plan of advanced chemotherapy resistant gastric cancer.
引文
[1]张玥,俞静.阿帕替尼治疗晚期恶性肿瘤的临床疗效及安全性观察[J].临床和实验医学杂志,2018,17(9):897-900.
[2]张喜爱.替吉奥联合阿帕替尼与单药替吉奥治疗晚期胃癌的疗效对比[J].罕少疾病杂志,2018,25(2):36-37,70.
[3]童辉,程红平.阿帕替尼治疗晚期化疗耐药胃癌的临床效果分析[J].药品评价,2018,15(8):34-36.
[4]方诚.阿帕替尼治疗晚期化疗耐药胃癌的临床效果观察[J].河南医学研究,2018,27(04):649-650.
[5]李晟,仲悦娇,滕悦,等.阿帕替尼联合化疗治疗晚期胃癌的疗效及预后观察[J].中国肿瘤临床与康复,2018, 25(1):44-46.
[6]赵鑫.阿帕替尼联合紫杉醇治疗晚期化疗耐药HER-2阴性胃癌的临床效果评价[J].中外医疗,2017,36(35):127-129.
[7]赵增虎,王明贤,宁宇,等.阿帕替尼联合安替可治疗耐药型进展期胃癌12例临床研究[J].中国中西医结合消化杂志,2017,25(7):502-505.
[8]孟长婷,赵林,白春梅.晚期胃癌应用阿帕替尼病例报告1例[J].中国肿瘤临床,2017,44(7):354.
[9]冯久桓,秦叔逵,王琳.甲磺酸阿帕替尼的研究现状与进展[J].临床肿瘤学杂志,2017,22(4):345-356.
[10]李倩.阿帕替尼治疗晚期化疗耐药胃癌的临床效果分析[J].影像研究与医学应用,2017,1(4):226-227.
[11]涂艳,彭枫.阿帕替尼治疗恶性肿瘤的临床研究进展[J].中国肿瘤临床,2016,43(12):545-548.
[12]杜娟,刘宝瑞.阿帕替尼治疗晚期化疗耐药胃癌的临床体会[J].现代肿瘤医学,2016,24(13):2100-2104.
[2]张喜爱.替吉奥联合阿帕替尼与单药替吉奥治疗晚期胃癌的疗效对比[J].罕少疾病杂志,2018,25(2):36-37,70.
[3]童辉,程红平.阿帕替尼治疗晚期化疗耐药胃癌的临床效果分析[J].药品评价,2018,15(8):34-36.
[4]方诚.阿帕替尼治疗晚期化疗耐药胃癌的临床效果观察[J].河南医学研究,2018,27(04):649-650.
[5]李晟,仲悦娇,滕悦,等.阿帕替尼联合化疗治疗晚期胃癌的疗效及预后观察[J].中国肿瘤临床与康复,2018, 25(1):44-46.
[6]赵鑫.阿帕替尼联合紫杉醇治疗晚期化疗耐药HER-2阴性胃癌的临床效果评价[J].中外医疗,2017,36(35):127-129.
[7]赵增虎,王明贤,宁宇,等.阿帕替尼联合安替可治疗耐药型进展期胃癌12例临床研究[J].中国中西医结合消化杂志,2017,25(7):502-505.
[8]孟长婷,赵林,白春梅.晚期胃癌应用阿帕替尼病例报告1例[J].中国肿瘤临床,2017,44(7):354.
[9]冯久桓,秦叔逵,王琳.甲磺酸阿帕替尼的研究现状与进展[J].临床肿瘤学杂志,2017,22(4):345-356.
[10]李倩.阿帕替尼治疗晚期化疗耐药胃癌的临床效果分析[J].影像研究与医学应用,2017,1(4):226-227.
[11]涂艳,彭枫.阿帕替尼治疗恶性肿瘤的临床研究进展[J].中国肿瘤临床,2016,43(12):545-548.
[12]杜娟,刘宝瑞.阿帕替尼治疗晚期化疗耐药胃癌的临床体会[J].现代肿瘤医学,2016,24(13):2100-2104.